Next Article in Journal
A Vaccine Strain of the A/ASIA/Sea-97 Lineage of Foot-and-Mouth Disease Virus with a Single Amino Acid Substitution in the P1 Region That Is Adapted to Suspension Culture Provides High Immunogenicity
Next Article in Special Issue
Enhancing COVID-19 Vaccines Acceptance: Results from a Survey on Vaccine Hesitancy in Northern Italy
Previous Article in Journal
The Potential Role of Nonhuman Primate Models to Better Comprehend Early Life Immunity and Maternal Antibody Transfer
Previous Article in Special Issue
Acceptance of a COVID-19 Vaccine in Japan during the COVID-19 Pandemic
Article

Soluble Spike DNA Vaccine Provides Long-Term Protective Immunity against SARS-CoV-2 in Mice and Nonhuman Primates

1
Research Institute, SL VaxiGen Inc., Korea Bio Park, Seongnam 13488, Korea
2
Research Institute, Genexine Inc., Korea Bio Park, Seongnam 13488, Korea
3
National Primate Research Centre, Korea Research Institute of Bioscience and Biotechnology, Cheongju, Chungcheongbuk 34141, Korea
4
Science Unit, International Vaccine Institute, Seoul 08826, Korea
5
GenNBio Inc., Seoul 06026, Korea
*
Author to whom correspondence should be addressed.
Academic Editors: Vasso Apostolopoulos, Steven B. Bradfute and Scott Anthony
Vaccines 2021, 9(4), 307; https://doi.org/10.3390/vaccines9040307
Received: 10 February 2021 / Revised: 18 March 2021 / Accepted: 20 March 2021 / Published: 24 March 2021
(This article belongs to the Collection COVID-19 Vaccines and Vaccination)
The unprecedented and rapid spread of SARS-CoV-2 (severe acute respiratory syndrome-coronavirus-2) has motivated the need for a rapidly producible and scalable vaccine. Here, we developed a synthetic soluble SARS-CoV-2 spike (S) DNA-based vaccine candidate, GX-19. In mice, immunization with GX-19 elicited not only S-specific systemic and pulmonary antibody responses but also Th1-biased T cell responses in a dose-dependent manner. GX-19-vaccinated nonhuman primates seroconverted rapidly and exhibited a detectable neutralizing antibody response as well as multifunctional CD4+ and CD8+ T cell responses. Notably, when the immunized nonhuman primates were challenged at 10 weeks after the last vaccination with GX-19, they had reduced viral loads in contrast to non-vaccinated primates as a control. These findings indicate that GX-19 vaccination provides a durable protective immune response and also support further development of GX-19 as a vaccine candidate for SARS-CoV-2. View Full-Text
Keywords: COVID-19; DNA vaccine COVID-19; DNA vaccine
Show Figures

Figure 1

MDPI and ACS Style

Seo, Y.B.; Suh, Y.S.; Ryu, J.I.; Jang, H.; Oh, H.; Koo, B.-S.; Seo, S.-H.; Hong, J.J.; Song, M.; Kim, S.-J.; Sung, Y.C. Soluble Spike DNA Vaccine Provides Long-Term Protective Immunity against SARS-CoV-2 in Mice and Nonhuman Primates. Vaccines 2021, 9, 307. https://doi.org/10.3390/vaccines9040307

AMA Style

Seo YB, Suh YS, Ryu JI, Jang H, Oh H, Koo B-S, Seo S-H, Hong JJ, Song M, Kim S-J, Sung YC. Soluble Spike DNA Vaccine Provides Long-Term Protective Immunity against SARS-CoV-2 in Mice and Nonhuman Primates. Vaccines. 2021; 9(4):307. https://doi.org/10.3390/vaccines9040307

Chicago/Turabian Style

Seo, Yong B., You S. Suh, Ji I. Ryu, Hwanhee Jang, Hanseul Oh, Bon-Sang Koo, Sang-Hwan Seo, Jung J. Hong, Manki Song, Sung-Joo Kim, and Young C. Sung. 2021. "Soluble Spike DNA Vaccine Provides Long-Term Protective Immunity against SARS-CoV-2 in Mice and Nonhuman Primates" Vaccines 9, no. 4: 307. https://doi.org/10.3390/vaccines9040307

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop